Great Collaboration and Important Update as TIRmed Pharma Strengthens Partnership with Zelmic
November 6, 2025
Zelmic is proud to announce the continued and expanded collaboration with TIRmed Pharma in the development of TIR-C, a novel topical oligonucleotide-based treatment for atopic dermatitis. This innovative drug candidate is designed to address the underlying causes of the disease, not just its symptoms, and has shown highly promising preclinical results — with five topical applications over two weeks providing up to 15 months of symptom relief.
Advancing toward clinical development
As part of the next stage in TIRmed Pharma’s clinical program, Zelmic is leading the development of GMP-compliant manufacturing processes for TIR-C. The collaboration includes both formulation development and clinical trial material production, ensuring the highest standards of product quality, stability, and regulatory compliance ahead of the planned Phase I clinical study.
“We are delighted to continue supporting TIRmed Pharma in developing this promising drug candidate,” says David Sagna, CEO of Zelmic. “Reliable manufacturing and analytical processes are crucial to ensuring quality and consistency ahead of entering clinical development, and we look forward to contributing our formulation expertise to this important project.”
A strong and trusted partnership
“The expanded partnership with Zelmic marks a milestone in the clinical development of TIR-C,” says Leo Holmgren, CEO of TIRmed Pharma. “Zelmic’s deep expertise in topical formulation development strengthens the foundation for our clinical program and supports our mission to improve treatment outcomes for patients with atopic dermatitis worldwide.”
About TIRmed Pharma
TIRmed Pharma is a biotechnology company developing next-generation immunomodulatory therapies for autoimmune skin diseases, with an initial focus on atopic dermatitis (eczema). The company’s drug candidate, TIR-C, is a topical oligonucleotide-based treatment that regulates immune responses and targets the disease’s underlying mechanisms. Promising preclinical results support its potential to provide long-lasting relief and reduce treatment burden. Building on expertise in immunology and drug development, the company is pioneering new solutions in dermatological immunotherapy to enable more targeted and effective treatment options. TIRmed Pharma is headquartered in Stockholm, Sweden. For more information, visit tirmedpharma.com and follow TIRmed on LinkedIn.
Zelmic – your end-to-end topical partner
As part of the CTR Group, Zelmic offers a complete pathway from preclinical formulation development to clinical material manufacture and combine scientific depth, regulatory experience, and operational agility. This collaboration reflects Zelmic’s commitment to advancing innovative topical treatments that improve patient outcomes and accelerate progress in dermatological drug development.
Read the full article here:
See all news